Good morning :)
Place Order
Add to Watchlist

Biocon Ltd

BIOCON Share Price

380.051.50% (+5.60)
High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP

With a market cap of ₹50,719 cr, stock is ranked 193

Stock is 2.63x as volatile as Nifty

BIOCON Stock Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Avg

Financials growth has been moderate for a few years

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Bad

The stock is overpriced and in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

With a market cap of ₹50,719 cr, stock is ranked 193

Stock is 2.63x as volatile as Nifty

BIOCON Performance & Key Metrics

BIOCON Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
50.052.010.30%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
37.156.590.82%

BIOCON Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 
73%
Analysts have suggested that investors can buy this stock

from 15 analysts

Price Upside

Earnings Growth

Rev. Growth

See Detailed Forecast

BIOCON Company Profile

Biocon Limited is a biopharmaceutical company engaged in the research & development and manufacture of pharmaceuticals, medicinal chemical and botanical products.

Investor Presentation

View older View older 

May 9, 2025

PDF
View Older Presentations

BIOCON Similar Stocks (Peers)

Compare with peers Compare with peers 

BIOCON Similar Stocks (Peers)

Compare with peers Compare with peers 
PE Ratio
-1,288.38
-1,288.38
1Y Return
18.22%
18.22%
Buy Reco %
100.00
100.00
PE Ratio
97.17
97.17
1Y Return
3.67%
3.67%
Buy Reco %
66.67
66.67
PE Ratio
57.88
57.88
1Y Return
61.38%
61.38%
Buy Reco %
100.00
100.00
PE Ratio
-300.29
-300.29
1Y Return
186.70%
186.70%
Buy Reco %
0.00
0.00
PE Ratio
55.57
55.57
1Y Return
28.52%
28.52%
Buy Reco %
0.00
0.00
Compare with Peers

BIOCON Sentiment Analysis

BIOCON Sentiment Analysis

New
Crisp summary & key insights to decode earnings calls instantly

BIOCON Stock Summary · February 2025

In Q3 FY25, the company demonstrated resilience with a 10% year-on-year revenue growth, primarily driven by robust performance in the Biosimilars and Research Services segments, despite facing challenges in Generics. Management remains optimistic about future growth, bolstered by successful FDA audits and a strong product pipeline, particularly in the insulin market, where strategic expansions are underway. While operational pressures have led to a profit before tax loss, increased investments in R&D and new facilities are expected to enhance production capabilities and market positioning. The company is also strategically targeting emerging markets and preparing for significant government tenders, reflecting a proactive approach to capitalize on growth opportunities amidst competitive dynamics. Overall, the sentiment remains positive, with expectations for stable revenue ratios and improved margins in the near term.

BIOCON Stock Growth Drivers
BIOCON Stock Growth Drivers
7
  • Regulatory and Operational Milestones

    The company has achieved significant regulatory milestones, including successful outcomes from multiple FDA audits and

  • Financial Performance and Growth

    The company reported a year-on-year operating revenue growth of 10% in the third quarter of

BIOCON Stock Challenges
BIOCON Stock Challenges
4
  • Declining Revenue in Generics Business

    The Generics business reported a year-on-year revenue decline of 2%, despite a 10% sequential growth

  • Increased Operating Expenses and R&D Investments

    The company has faced higher operating expenses associated with new facilities and increased R&D investments,

BIOCON Forecast

BIOCON Forecasts

Price

Revenue

Earnings

BIOCON

BIOCON

Income

Balance Sheet

Cash Flow

BIOCON Income Statement

BIOCON Income Statement

Industry refers to the sub-sector this company belongs to.
Lower than Industry Revenue Growth
A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 20.47%, vs industry avg of 21.18%

Decreasing Market Share
Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 77.66% to 75.4%

Lower than Industry Net Income
Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 6.25%, vs industry avg of 20.36%

Loading...

Financial YearFY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025TTM
Total Revenue4,064.504,350.905,854.306,529.407,410.208,396.7011,550.1015,621.2016,566.4016,596.90
Raw Materialssubtract1,515.601,677.802,106.302,190.302,533.802,975.003,817.205,754.6012,095.4012,125.90
Power & Fuel Costsubtract156.40189.00239.80246.10270.30316.40414.80388.90
Employee Costsubtract747.00931.101,165.301,458.801,741.001,880.102,181.002,664.10
Selling & Administrative Expensessubtract540.10519.30846.70952.701,041.701,158.101,338.601,725.80
Operating & Other expensessubtract-47.50-22.90-237.40-121.60-17.10202.201,369.301,019.40
Depreciation/Amortizationsubtract277.20385.10447.80552.20715.10814.201,113.101,568.801,687.001,687.00
Interest & Other Itemssubtract26.0061.5070.9064.9057.7067.60419.00974.40897.40897.40
Taxes & Other Itemssubtract237.60237.60309.60437.80327.20334.70434.40502.70873.30873.30
EPS5.103.107.546.236.175.403.858.528.468.44
DPS0.500.500.500.000.000.501.500.501.250.50
Payout ratio0.100.160.070.000.000.090.390.060.150.06

BIOCON Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2025FY 2025

Annual Report Pending

Investor Presentation

May 9PDF
FY 2024FY 2024

Annual report

PDF

Investor Presentation

Aug 11PDF
FY 2023FY 2023

Annual report

PDF

Investor Presentation

May 24PDF
Feb 17PDF
Nov 15PDF
Jul 27PDF
FY 2022FY 2022

Annual report

PDF

Investor Presentation

Apr 29PDF
Apr 28PDF
Mar 1PDF
Feb 28PDF
FY 2021FY 2021

Annual report

PDF
FY 2020FY 2020

Annual report

PDF
FY 2019FY 2019

Annual report

PDF
FY 2018FY 2018

Annual report

PDF
FY 2017FY 2017

Annual report

PDF
FY 2016FY 2016

Annual report

PDF
FY 2015FY 2015

Annual report

PDF
 

BIOCON Stock Peers

BIOCON Past Performance & Peer Comparison

BIOCON Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CareBiotechnology

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Biocon Ltd50.052.010.30%
Onesource Specialty Pharma Ltd-1,288.3858.48
Sai Life Sciences Ltd97.1716.95
Acutaas Chemicals Ltd57.8813.450.12%

BIOCON Stock Price Comparison

Compare BIOCON with any stock or ETF
Compare BIOCON with any stock or ETF
BIOCON
Loading...

BIOCON Holdings

BIOCON Shareholdings

BIOCON Promoter Holdings Trend

BIOCON Promoter Holdings Trend

Decreased Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has decreased by 6.18%

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

BIOCON Institutional Holdings Trend

BIOCON Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Increased Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has increased by 1.34%

Tickertape Separator

BIOCON Shareholding Pattern

BIOCON Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding54.45%13.82%7.64%7.00%17.09%

Sep 2024

Dec 2024

Mar 2025

Jun 2025

BIOCON Shareholding History

BIOCON Shareholding History

MarJunSepDec '24MarJun5.63%5.90%5.93%5.66%5.66%7.00%

Mutual Funds Invested in BIOCON

Mutual Funds Invested in BIOCON

No mutual funds holding trends are available

Top 5 Mutual Funds holding Biocon Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
1.2926%1.44%-0.05%12/108 (+2)
0.8608%1.61%-0.11%25/71 (-5)
0.6636%0.95%0.01%87/150 (0)

Compare 3-month MF holding change on Screener

BIOCON Insider Trades & Bulk Stock Deals

BIOCON Insider Trades & Bulk Stock Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases containing BIOCON stock

smallcases containing BIOCON stock

Looks like this stock is not in any smallcase yet.

BIOCON Events

BIOCON Events

BIOCON Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

BIOCON Dividend Trend

No dividend trend available

BIOCON Upcoming Dividends

BIOCON Upcoming Dividends

No upcoming dividends are available

BIOCON Past Dividends

BIOCON Past Dividends

Cash Dividend

Ex DateEx DateJul 4, 2025

Final
Final | Div/Share: ₹0.50

Dividend/Share

0.50

Ex DateEx Date

Jul 4, 2025

Cash Dividend

Ex DateEx DateJul 5, 2024

Final
Final | Div/Share: ₹0.50

Dividend/Share

0.50

Ex DateEx Date

Jul 5, 2024

Cash Dividend

Ex DateEx DateJul 7, 2023

Final
Final | Div/Share: ₹1.50

Dividend/Share

1.50

Ex DateEx Date

Jul 7, 2023

Cash Dividend

Ex DateEx DateJun 30, 2022

Final
Final | Div/Share: ₹0.50

Dividend/Share

0.50

Ex DateEx Date

Jun 30, 2022

Cash Dividend

Ex DateEx DateJul 18, 2019

Final
Final | Div/Share: ₹0.50

Dividend/Share

0.50

Ex DateEx Date

Jul 18, 2019

BIOCON Stock News & Opinions

BIOCON Stock News & Opinions

Spotlight
Biocon Ltd spurts 1.07%, gains for fifth straight session

Biocon Ltd is up for a fifth straight session today. The stock is quoting at Rs 372.5, up 1.07% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.26% on the day, quoting at 25518.4. The Sensex is at 83618.54, up 0.25%. Biocon Ltd has gained around 10.73% in last one month. Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has gained around 3.84% in last one month and is currently quoting at 22110.8, up 0.37% on the day. The volume in the stock stood at 26.19 lakh shares today, compared to the daily average of 65 lakh shares in last one month. The benchmark July futures contract for the stock is quoting at Rs 374.3, up 1.3% on the day. Biocon Ltd is up 3.1% in last one year as compared to a 5% jump in NIFTY and a 9.9% jump in the Nifty Pharma index.The PE of the stock is 0 based on TTM earnings ending March 25.Powered by Capital Market - Live

3 days agoCapital Market - Live
Live Market Update
Nifty above 25,550 mark; oil & gas shares jump

The key equity benchmarks traded with moderate gains in morning trade. The Nifty traded above the 25,550 mark. Oil & gas shares jumped after declining in the past trading session. At 10:25 IST, the barometer index, the S&P BSE Sensex advanced 278.10 points or 0.33% to 83,687.79. The Nifty 50 index jumped 107.55 points or 0.43% to 25,561.55. In the broader market, the S&P BSE Mid-Cap index rose 0.43% and the S&P BSE Small-Cap index jumped 0.44%. The market breadth was positive. On the BSE 2,102 shares rose and 1,406 shares fell. A total of 209 shares were unchanged. New Listing: Shares of Indogulf Cropsciences were currently trading at Rs 109.50 at 10:27 IST on the BSE, representing a discount of 1.35% compared with the issue price of Rs 111. The scrip was listed at 111, matching the initial public offer (IPO) price. So far, the stock has hit a high of Rs 112.60 and a low of Rs 105.45. On the BSE, over 4.45 lakh shares of the company were traded in the counter so far. Buzzing Index: The Nifty Oil & Gas index advanced 0.70% to 11,921.55. The index declined 0.17% in the past trading session. Oil India (up 2.24%), Oil & Natural Gas Corpn (up 1.29%), GAIL (India) (up 1.18%), Gujarat State Petronet (up 1.06%), Gujarat Gas (up 0.92%), Bharat Petroleum Corporation (up 0.6%), Hindustan Petroleum Corporation (up 0.4%), Adani Total Gas (up 0.35%), Reliance Industries (up 0.31%) and Mahanagar Gas (up 0.24%) surged. Stocks in Spotlight: Biocon rose 0.42%. The company said that Biocon Biologics has received the European Commission (EC) marketing authorisation in the European Union (EU) for Vevzuo and Evfraxy biosimilars of Denosumab. Rail Vikas Nigam added 0.32%. The company said that its board has approved the appointment of Chandan Kumar Verma as chief financial officer (CFO) with effect from 2 July 2025.Powered by Capital Market - Live

3 days agoCapital Market - Live
Spotlight
Biocon's biologics arm gets regulatory approval in EU for Denosumab biosimilars

Denosumab is a human monoclonal antibody that targets and binds a protein known as RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand). RANKL plays a crucial role in the formation, function, and survival of osteoclasts, which are the cells responsible for bone resorption. By blocking RANKL, denosumab effectively inhibits the breakdown of bone, leading to increased bone mass and strength. Vevzuo is authorised for the prevention of bone complications in adults with advanced cancer involving bone and the treatment of adults and skeletally mature adolescents with giant cell tumour (GCT) of bone. Evfraxy is authorised for the treatment of osteoporosis in men and postmenopausal women, the treatment of bone loss linked to hormone ablation in men with prostate cancer at increased risk of fractures or treatment of bone loss associated with long-term systemic glucocorticoid therapy in adults. Clinical data showed that both Denosumab biosimilars have comparable quality, safety, and efficacy to the reference product. The marketing authorisation follows a positive opinion issued by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on April 25, 2025. Shreehas Tambe, CEO & managing director, Biocon Biologics, said: 'The approval of Vevzuo and Evfraxy in Europe underscores our strong scientific expertise and commitment to expanding patient access to essential medicines, including to new therapeutic areas such as bone health. In the past 18 months, we have successfully secured regulatory approvals for three biosimilars in Europe and two in the UK. These Denosumab biosimilars mark another significant milestone in our rapid expansion, and support for healthcare systems in the region.' Biocon is a global biopharma company dedicated to improving affordable access to therapies for chronic conditions like diabetes, cancer, and autoimmune diseases. The company's consolidated net profit surged 154.2% to Rs 344.50 crore on a 12.8% jump in net sales to Rs 4,358.10 crore in Q4 FY25 over Q4 FY24. The scrip shed 0.20% to currently trade at Rs 367.65 on the BSE. Powered by Capital Market - Live

3 days agoCapital Market - Live
Spotlight
Biocon's biologics arm gets Health Canada approval for aflibercept biosimilar 'Yesafili'

This approval paves the way for the launch of YESAFILI in Canada, scheduled for 04 July 2025. YESAFILI is the first biosimilar to EYLEA to be approved by Health Canada. YESAFILI is a vascular endothelial growth factor (VEGF) inhibitor. It is prescribed for the treatment of several eye conditions. These include neovascular (wet) age-related macular degeneration (AMD). It also treats visual impairment caused by macular edema secondary to central retinal vein vein occlusion (CRVO). Visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO) is another indication. Furthermore, it is used for diabetic macular edema (DME). It also treats myopic choroidal neovascularization (myopic CNV). The approval is based on a comprehensive package of analytical, nonclinical, and clinical data, confirming that YESAFILI is highly similar with no clinically meaningful differences to EYLEA in terms of quality, safety, and efficacy. Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd., said: 'The approval of YESAFILI by Health Canada'the first biosimilar to EYLEA in Canada'is a proud moment for Biocon Biologics. We are excited that in July, Canada will be the first country where we will launch YESAFILI, making it our 10th biosimilar to be commercialized worldwide.' Biocon is a global biopharma company dedicated to improving affordable access to therapies for chronic conditions like diabetes, cancer, and autoimmune diseases. The company's consolidated net profit surged 154.2% to Rs 344.50 crore on a 12.8% jump in net sales to Rs 4,358.10 crore in Q4 FY25 over Q4 FY24. The scrip rose 0.96% to currently trade at Rs 353.90 on the BSE. Powered by Capital Market - Live

1 week agoCapital Market - Live
Spotlight
Biocon raises Rs 4,500 crore via QIP

Biocon has successfully concluded a Qualified Institutions Placement (QIP), raising Rs 4,500 crore (approximately $523 million), marking its first equity fundraise since its IPO in 2004. The company issued 13.63 crore equity shares at Rs 330 per share. The QIP opened on June 16 and closed on June 19, attracting participation from a mix of domestic and foreign institutional investors. Major names in the final orderbook included SBI Mutual Fund, ICICI Prudential Mutual Fund, HDFC Life, Nippon India Mutual Fund, Mirae Asset, Franklin Templeton, SBI General Insurance, Government Pension Fund Global, and BlackRock. The proceeds from the fundraise will be used for multiple strategic objectives, including purchasing optionally convertible debentures of Biocon Biologics from Goldman Sachs-managed funds, repaying certain borrowings, and meeting other financial and corporate needs. Following the issue, the combined stake of the promoter and promoter group stands at 54.45%, down from 60.64% as of March 2025. Siddharth Mittal, CEO and managing director, Biocon, said, The strong response to our QIP reflects deep investor conviction in Biocon's differentiated strategy and consistent execution. This capital raise further strengthens our balance sheet, enabling us to invest in innovation, expand global access to lifesaving biopharmaceuticals, and advance our purpose of delivering affordable healthcare solutions that address pressing health inequities worldwide. Biocon is a global biopharma company dedicated to improving affordable access to therapies for chronic conditions like diabetes, cancer, and autoimmune diseases. The company's consolidated net profit surged 154.2% to Rs 344.50 crore on a 12.8% jump in net sales to Rs 4,358.10 crore in Q4 FY25 over Q4 FY24. The scrip rose 0.86% to settle at Rs 351.60 on Friday, 20 June 2025. Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Corporate
Biocon get facilities rated

CRISIL Ratings Limited has re-affirmed the Long Term rating of Biocon at CRISIL AA+/Stable and short term rating at CRISIL A1+.Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Spotlight
Biocon Ltd soars 3.52%, Gains for third straight session

Biocon Ltd is up for a third straight session in a row. The stock is quoting at Rs 353.2, up 3.52% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.42% on the day, quoting at 25209.65. The Sensex is at 82725.53, up 0.41%. Biocon Ltd has added around 7.63% in last one month. Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has added around 4.53% in last one month and is currently quoting at 21948, up 0.51% on the day. The volume in the stock stood at 47.75 lakh shares today, compared to the daily average of 26.07 lakh shares in last one month. The benchmark June futures contract for the stock is quoting at Rs 354.1, up 3.46% on the day. Biocon Ltd is up 4.22% in last one year as compared to a 8.09% gain in NIFTY and a 11.76% gain in the Nifty Pharma index.The PE of the stock is 0 based on TTM earnings ending March 25.Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Spotlight
Biocon gets CDSCO approval for Liraglutide drug substance

Additionally, its wholly owned subsidiary, Biocon Pharma, has received CDSCO approval for the Liraglutide drug product (6 mg/ml solution for injection in pre-filled pen and cartridge). The said approval is for the generic version of Victoza, indicated for the treatment of insufficiently controlled type 2 diabetes mellitus in adults, adolescents and children aged 10 years and above, as an adjunct to diet and exercise. The approval was received from the CDSCO under the recently formulated 101 route that enables recognition of approvals granted by established and referenced serious regulatory authorities. Siddharth Mittal, chief executive officer and managing director, Biocon, said: 'The approval of our first vertically integrated GLP-1 in India, Liraglutide, is another significant step forward in expanding access of this product to patients suffering from diabetes. India has one of the highest number of people with diabetes globally, with estimates exceeding 77 million cases, and expected to rise further. The approval enables us to address a critical need by making this drug available, and aligns with Biocon's mission to provide affordable, lifesaving medications to those who need it the most. We are now gearing up to launch the product expeditiously through our commercialization partners in India.' Biocon is an innovation-led global biopharmaceutical company focused on improving affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune diseases. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets, as well as generic formulations in the U.S. and Europe The company's consolidated net profit surged 154.2% to Rs 344.50 crore on 12.8% jump in net sales to Rs 4,358.10 crore in Q4 FY25 over Q4 FY24. The counter shed 0.45% to end at Rs 334.05 on the BSE.Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Biocon Ltd spurts 1.3%, up for five straight sessions

Biocon Ltd rose for a fifth straight session today. The stock is quoting at Rs 343.8, up 1.3% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.07% on the day, quoting at 25003.4. The Sensex is at 82230.01, down 0.12%. Biocon Ltd has added around 3.59% in last one month. Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has added around 2.33% in last one month and is currently quoting at 21633.2, up 1% on the day. The volume in the stock stood at 7.5 lakh shares today, compared to the daily average of 36.71 lakh shares in last one month. The benchmark May futures contract for the stock is quoting at Rs 344.85, up 1.2% on the day. Biocon Ltd is up 11.77% in last one year as compared to a 10.98% gain in NIFTY and a 13.77% gain in the Nifty Pharma index.The PE of the stock is 0 based on TTM earnings ending March 25.Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Biocon's subsidiary get US FDA nod for anticoagulant medication Rivaroxaban

Rivaroxaban is a prescription medication used in the treatment of deep vein thrombosis and pulmonary embolism, to reduce the risk of stroke and systemic embolism in nonvalvular atrial fibrillation. The approval will further strengthen Biocon's portfolio of vertically integrated drug products,' the company said in a statement. Biocon is an innovation-led global biopharmaceuticals company engaged in the production of therapies for chronic conditions like diabetes, cancer, and autoimmune diseases. It has developed and commercialized novel biologics, biosimilars, and complex small-molecule APIs in India and several key global markets, as well as generic formulations in the US, Europe, & key emerging markets. The company's consolidated net profit surged 154.24% to Rs 344.50 crore in Q4 FY25, compared with Rs 135.50 crore in Q4 FY24. Revenue from operations increased 12.76% YoY to Rs 4,417 crore during the period under review. The scrip rose 0.89% to currently trade at Rs 341.55 on the BSE. Powered by Capital Market - Live

1 month agoCapital Market - Live

Frequently asked questions

Frequently asked questions

  1. What is the share price of Biocon Ltd (BIOCON) today?

    The share price of BIOCON as on 4th July 2025 is ₹380.05. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on Biocon Ltd (BIOCON) share?

    The past returns of Biocon Ltd (BIOCON) share are
    • Past 1 week: 6.41%
    • Past 1 month: 10.70%
    • Past 3 months: 15.94%
    • Past 6 months: 6.13%
    • Past 1 year: 5.19%
    • Past 3 years: 22.08%
    • Past 5 years: -5.42%

  3. What are the peers or stocks similar to Biocon Ltd (BIOCON)?
  4. What is the dividend yield % of Biocon Ltd (BIOCON) share?

    The current dividend yield of Biocon Ltd (BIOCON) is 0.30.

  5. What is the market cap of Biocon Ltd (BIOCON) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Biocon Ltd (BIOCON) is ₹50719.74 Cr as of 4th July 2025.

  6. What is the 52 week high and low of Biocon Ltd (BIOCON) share?

    The 52-week high of Biocon Ltd (BIOCON) is ₹404.70 and the 52-week low is ₹291.

  7. What is the PE and PB ratio of Biocon Ltd (BIOCON) stock?

    The P/E (price-to-earnings) ratio of Biocon Ltd (BIOCON) is 50.05. The P/B (price-to-book) ratio is 2.01.

  8. Which sector does Biocon Ltd (BIOCON) belong to?

    Biocon Ltd (BIOCON) belongs to the Health Care sector & Biotechnology sub-sector.

  9. How to buy Biocon Ltd (BIOCON) shares?

    You can directly buy Biocon Ltd (BIOCON) shares on Tickertape. Simply sign up, connect your demat account and place your order.